Navigation Links
CSV-1OOOE Contrast Sensitivity Test Face

ProductsCSV-1OOOE Contrast Sensitivity Test Face
Company VectorVision
Item CSV-1OOOE Contrast Sensitivity Test Face
Features Inquire
Description The CSV-1000E contrast sensitivity chart test face is the most widely used contrast sensitivity test in the world. This test provides for four (4) rows of sine-wave gratings. At the recommended test distance of 8 ft (2.5 meters), these gratings test the spatial frequencies of 3, 6, 12 and 18 cycles/degree. The CSV-1000E provides a full contrast sensitivity curve, which is very useful for the evaluation of ocular disease (particularly cataracts, glaucoma, optic neuritis, diabetes and macular degeneration), contact lenses and refractive surgery. For cataract evaluation/documentation, a functional acuity score can be obtained directly from the test scoring sheet.

For those interested in using the CSV-1000E in research studies, the test face is available in two versions. The CSV-1000E Contrast Sensitivity Chart 1 provides randomized locations for the grating targets.

Info VectorVision
Customer Service: (800) 526-7703
Web site: http://www.vectorvision.com

Related medicine products :

1. Low Contrast Flip Chart with Lea Symbols
2. Low Contrast Flip Chart Recording Pad
3. Low Contrast Flip Chart with Lea Numbers
4. Low Contrast Flip Chart with a different sequence of Lea Numbers
5. Functional Acuity Contrast Test
6. Letter Contrast Acuity Test
7. Sine Wave Contrast Test
8. CFI Plan Fluor Series for Phase Contrast (DL)
9. CFI Plan Fluor ELWD Series for Brightfield/Phase Contrast (DM/DLL)
10. CFI Achromat Series for Brightfield/Phase Contrast (DL)
11. CFI Plan Achromat Series for Brightfield/Phase Contrast (DL)
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, ... of a new charity campaign. As part of their ongoing community involvement program, ... the belief that children deserve a voice, and in the spirit of neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton ... for pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, in ... manufacturers step up to semi-automatic or fully-automatic case packing with a small footprint, ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... YORK, Pa. , Feb. 8, 2016  Unilife Corporation ... developer and supplier of injectable drug delivery systems, today announced ... and six months ended December 31, 2015 after market close ... not scheduled a conference call to discuss these financial results.  ... About Unilife Corporation --> About Unilife ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
(Date:2/8/2016)... Feb. 8, 2016  CTI BioPharma Corp. (CTI BioPharma) ... written communication from the U.S. Food and Drug Administration ... placed a partial clinical hold on the clinical studies ... application for pacritinib. This clinical hold impacts part of ... and will also affect planned clinical trials. ...
Breaking Medicine Technology: